Speaker Profile
M.D., Clinical Professor of Medicine, Yale School of Medicine
Biography
William K. Oh, M.D., is currently the Director of Precision Medicine at Yale Cancer Center and a Professor of Medicine (Medical Oncology) at Yale School of Medicine, roles he assumed in October 2024. As part of a newer initiative at Yale, he is focused on building a cohesive program in precision cancer medicine that integrates basic and translational science, clinical trials, and Smilow Cancer Hospital’s Precision Medicine Tumor Board. A central goal of his work is to increase the routine use of molecular and genetic testing for all cancer patients to improve outcomes. Dr. Oh is also dedicated to delivering multidisciplinary care for prostate cancer patients, a priority he has maintained for over 25 years. He has been recognized as a Top Doctor by Castle Connolly, New York Magazine, and Super Doctors. Additionally, he continues his commitment to teaching and advancing research in the field.
Previously, Dr. Oh was a Clinical Professor of Medicine at Icahn School of Medicine. He is an internationally recognized medical oncologist with extensive experience in clinical and translational research, holding leadership roles in both academia and industry. He has authored more than 350 articles, reviews, books, and book chapters related to genitourinary cancers. Dr. Oh has conducted numerous clinical cancer trials and served in key invited roles for ASCO, ACS, and AUA. He has also held the position of Chief Medical Officer for Sema4, a genomics and health intelligence company, as well as the Prostate Cancer Foundation.
Session Abstract – PMWC 2025 Silicon Valley
Track Chair:
- William Oh, Yale Cancer Center
Patient-centric data, such as Real-World Evidence (RWE) and Real-World Data (RWD), has become critical in reshaping drug development and healthcare decision-making. Over the last few years, regulatory agencies like the FDA and EMA have increasingly embraced RWE/RWD for decision-making processes, influencing everything from new drug indications to post-marketing surveillance. The integration of RWE and RWD is not only supporting clinical trial design and regulatory approvals, but also enabling precision medicine by providing deeper insights into patient subpopulations and their outcomes
Sessions:
- PMWC 2025 Award Ceremony
Pioneer Honoree: Isaac Kohane, Harvard
- Keynote: Can AI succeed where humans have failed to personalize medicine?
- Isaac Kohane, Harvard
- From Data to Decisions: Real-Time Patient Insights for Improved Care (PANEL)
Chair: Michael Pfeffer, Stanford Medicine
- Chris Longhurst, UC San Diego Health
- Tanya Townsend, Stanford Children’s
- Kiran Mysore, Sutter Health
- Cherodeep Goswami, UW Health - AI-Powered RWE: Driving Trustworthy Insights and Innovation through Interoperability (PANEL)
Chair: Charles Jaffe, HL7 International
- Chris Longhurst, UC San Diego Health
- Donald Rucker, 1upHealth
- Stan Huff, Graphite Health
- John Ioannidis, Stanford
- Chris Boone, Oracle
- Accelerating Drug Development with Real World Evidence and AI: Amgen's Journey
- Brian Bradbury, Amgen
- AI-Powered RWE: Accelerating Drug Development and Post-Market Applications (PANEL)
Chair: Erik Reinertsen, Demand Discovery Group
- Michelle Chen, Insilico Medicine
- Jun Jeon, Khosla Ventures
- Dan Riskin, Verantos
- Andrew Trister, Verily - Advancing Patient-Centered Outcomes with AI and Real-World Data Integration
- Phil Johnson, Evidation Health
- Leveraging AI and Real-World Evidence to Transform Patient Care in Oncology
- Amrita Basu, UCSF
- How to Implement AI for Faster Readout of Clinical Trails
Chair:William Oh, Yale
- Jennifer Webster, Pfizer
- Brandon Allgood, Parabilis Medicines
- Julian Hong, UCSF
- Michiel Niesen, nference
